Company News
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.
An European Patent for LTS’ application relating to an asenapine transdermal therapeutic system (TTS).
LTS congratulates its business partner Dr. Reddy’s Laboratories Ltd. for the US launch of its Buprenorphine and Naloxone Sublingual Film.
The new LTS webinar “Oral Thin Films – Tailoring Therapy Need” presented by Dr. Marco Emgenbroich will be held on Nov. 29, 3pm CET/ 9am EST. Join our free webinar.
At the meeting of the LTS Supervisory Board on April 23rd 2018, Prof. Dr. Norbert Loos resigned as Chairman of the Supervisory Board of the LTS AG. Subsequently, the LTS AG Supervisory Board elected Prof. Dr. Christof Hettich as its new Chairman.
